Preclinical toxicology and safety pharmacology of the first-in-class GADD45β/MKK7 inhibitor and clinical candidate, DTP3
- Submitting institution
-
Coventry University
- Unit of assessment
- 3 - Allied Health Professions, Dentistry, Nursing and Pharmacy
- Output identifier
- 31555102
- Type
- D - Journal article
- DOI
-
10.1016/j.toxrep.2019.04.006
- Title of journal
- Toxicology Reports
- Article number
- -
- First page
- 369
- Volume
- 6
- Issue
- -
- ISSN
- 2214-7500
- Open access status
- Compliant
- Month of publication
- April
- Year of publication
- 2019
- URL
-
-
- Supplementary information
-
-
- Request cross-referral to
- -
- Output has been delayed by COVID-19
- No
- COVID-19 affected output statement
- -
- Forensic science
- No
- Criminology
- No
- Interdisciplinary
- No
- Number of additional authors
-
27
- Research group(s)
-
-
- Citation count
- 4
- Proposed double-weighted
- No
- Reserve for an output with double weighting
- No
- Additional information
- -
- Author contribution statement
- This publication details initial findings from the first-in-human study of this peptide inhibitor to achieve clinical proof-of-concept for a cancer- selective NF-κB-targeting strategy to treat multiple myeloma. My role in this study was to analyse patient samples enrolled in this trial. I purified malignant CD138+ cells and normal CD20+ B cells/PBMCs from bone marrow aspirates and blood samples, respectively. These samples were then analysed by fluorescence-activated cell sorting (FACS) for phospho-JNK and cleaved caspase 3 levels in order to evaluate the cancer-selective pharmacodynamic response to DTP3. I also contributed to the initial paper draft.
- Non-English
- No
- English abstract
- -